Sacubitril/valsartan reverses cardiac structure and function in experimental model of hypertension-induced hypertrophic cardiomyopathy.

Autor: Jeremic J; Department of Pharmacy, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia.; Center of Excellence for Redox Balance Research, Cardiovascular and Metabolic Disorders, Kragujevac, Serbia., Govoruskina N; Federal Clinical Center for High Medical, Technologies Federal Health Biological Agency, Moscow, Russia., Bradic J; Department of Pharmacy, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia.; Center of Excellence for Redox Balance Research, Cardiovascular and Metabolic Disorders, Kragujevac, Serbia., Milosavljevic I; Department of Pharmacy, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia.; Center of Excellence for Redox Balance Research, Cardiovascular and Metabolic Disorders, Kragujevac, Serbia., Srejovic I; Center of Excellence for Redox Balance Research, Cardiovascular and Metabolic Disorders, Kragujevac, Serbia.; Department of Physiology, Faculty of Medical Sciences, University of Kragujevac, 34000, Kragujevac, Serbia.; Department of Pharmacology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia., Zivkovic V; Center of Excellence for Redox Balance Research, Cardiovascular and Metabolic Disorders, Kragujevac, Serbia.; Department of Physiology, Faculty of Medical Sciences, University of Kragujevac, 34000, Kragujevac, Serbia.; Department of Pharmacology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia., Jeremic N; Department of Pharmacy, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia.; Center of Excellence for Redox Balance Research, Cardiovascular and Metabolic Disorders, Kragujevac, Serbia.; I.M. Sechenov First Moscow State Medical University, Moscow, Russia., Nikolic Turnic T; Department of Pharmacy, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia.; Center of Excellence for Redox Balance Research, Cardiovascular and Metabolic Disorders, Kragujevac, Serbia.; F.F. Erismann Institute of Public Health, N.A. Semashko Public Health and Healthcare Department, I.M. Sechenov First Moscow State Medical University, Moscow, Russia., Tanaskovic I; Department of Histology and Embryology, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia., Bolevich S; Department of Pharmacology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia.; Department of Pathophysiology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia., Jakovljevic V; Center of Excellence for Redox Balance Research, Cardiovascular and Metabolic Disorders, Kragujevac, Serbia. drvladakgbg@yahoo.com.; Department of Physiology, Faculty of Medical Sciences, University of Kragujevac, 34000, Kragujevac, Serbia. drvladakgbg@yahoo.com.; Department of Human Pathology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia. drvladakgbg@yahoo.com., Bolevich S; Department of Human Pathology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia., Zivanovic MN; Institute for Information Technologies Kragujevac, University of Kragujevac, Kragujevac, Serbia.; BioIRC - Bioengineering Research and Development Center, University of Kragujevac, Kragujevac, Serbia., Okwose N; Translational and Clinical Research Instutute, Faculty of Medical Sciences, Newcastle University and Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UK., Seklic D; Institute for Information Technologies Kragujevac, University of Kragujevac, Kragujevac, Serbia., Milivojevic N; Institute for Information Technologies Kragujevac, University of Kragujevac, Kragujevac, Serbia., Grujic J; Institute for Information Technologies Kragujevac, University of Kragujevac, Kragujevac, Serbia., Velicki L; Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia.; Institute of Cardiovascular Diseases of Vojvodina, Sremska Kamenica, Serbia., MacGowan G; Translational and Clinical Research Instutute, Faculty of Medical Sciences, Newcastle University and Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UK., Jakovljevic DG; Translational and Clinical Research Instutute, Faculty of Medical Sciences, Newcastle University and Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UK.; Faculty Research Centre (CSELS), Faculty of Health and Life Sciences, Institute for Health and Wellbeing (CSELS), Coventry University, London, UK., Filipovic N; BioIRC - Bioengineering Research and Development Center, University of Kragujevac, Kragujevac, Serbia.; Faculty of Engineering, University of Kragujevac, Kragujevac, Serbia.
Jazyk: angličtina
Zdroj: Molecular and cellular biochemistry [Mol Cell Biochem] 2023 Dec; Vol. 478 (12), pp. 2645-2656. Date of Electronic Publication: 2023 Mar 30.
DOI: 10.1007/s11010-023-04690-7
Abstrakt: This study evaluated the effect of sacubtril/valsartan on cardiac remodeling, molecular and cellular adaptations in experimental (rat) model of hypertension-induced hypertrophic cardiomyopathy. Thirty Wistar Kyoto rats, 10 healthy (control) and 20 rats with confirmed hypertension-induced hypertrophic cardiomyopathy (HpCM), were used for this study. The HpCM group was further subdivided into untreated and sacubitril/valsartan-treated groups. Myocardial structure and function were assessed using echocardiography, Langendorff's isolated heart experiment, blood sampling and qualitative polymerase chain reaction. Echocardiographic examinations revealed protective effects of sacubitril/valsartan by improving left ventricular internal diameter in systole and diastole and fractional shortening. Additionally, sacubitril/valsartan treatment decreased systolic and diastolic blood pressures in comparison with untreated hypertensive rats. Moreover, sacubitril/valsartan treatment reduced oxidative stress and apoptosis (reduced expression of Bax and Cas9 genes) compared to untreated rats. There was a regular histomorphology of cardiomyocytes, interstitium, and blood vessels in treated rats compared to untreated HpCM rats which expressed hypertrophic cardiomyocytes, with polymorphic nuclei, prominent nucleoli and moderately dilated interstitium. In experimental model of hypertension-induced hypertrophic cardiomyopathy, sacubitril/valsartan treatment led to improved cardiac structure, haemodynamic performance, and reduced oxidative stress and apoptosis. Sacubitril/valsartan thus presents as a potential therapeutic strategy resulted in hypertension-induced hypertrophic cardiomyopathy.
(© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz: